Rajkot News Today

Hepatic Encephalopathy Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Healt

 Breaking News
  • No posts were found

Hepatic Encephalopathy Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Healt

November 15
00:08 2022
Hepatic Encephalopathy Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies - Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Healt
The growing market of Hepatic Encephalopathy is expected to surge mainly due to the rising prevalence of Hepatic Encephalopathy and aging population, increased R&D activities and launch of upcoming therapies like Rifaximin, AXA1665, GR3027 with key pharmaceuticals such as Axcella Health, Umecrine Cognition, Vedanta Biosciences, and others.

DelveInsight’s Hepatic Encephalopathy Marketreport delivers an in-depth understanding of current treatment practices, emerging drugs, Hepatic Encephalopathy market share of the individual therapies, current and forecasted Hepatic Encephalopathy market size from 2019 to 2032 segmented into the 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].

 

Hepatic Encephalopathy: Overview

Hepatic Encephalopathy (HE) is a brain disorder that develops in people suffering from liver disease. Hepatic Encephalopathy presents a spectrum of neuropsychiatric symptoms that lie from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease.

It is found in Hepatic Encephalopathy, the incidence of acute liver failure, liver bypass procedures, and cirrhosis are categorized as Type A, B, and C Hepatic Encephalopathy, respectively. Also, Hepatic Encephalopathy can be classified according to whether it is present as overt or covert.

 

Some of the key takeaways from the Hepatic Encephalopathy Market Report: 

  • The Hepatic Encephalopathy market size was evaluated to be USD 1,448 million in 2020 in the 7MM market by DelveInsight.  The market size of Hepatic Encephalopathy is expected to grow at a CAGR of 5.31%  in the 7MM for the study period 2018-2030.
  • According to an estimate by DelveInsight, the highest diagnosed Hepatic Encephalopathy prevalent cases in the 7MM were found in the United States with 205,018 cases in 2020.
  • The increase in market size of Hepatic Encephalopathy is a direct consequence of the expected approval of emerging therapies and the increasing patient population of Hepatic Encephalopathy in the 7MM.
  • The expected approval of potential therapies such as GR3027 (Golexanolone), Rifaximin (SSD), AXA1665, VE303 may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hepatic Encephalopathy.
  • Key pharma players working proactively in the Hepatic Encephalopathy therapeutic market are Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Health/Salix Pharmaceuticals and others that have the potential to create a significant positive shift in the market size. 
  • According to DelveInsight’s analysis, the diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM is expected to increase at a CAGR of 0.61% for the study period of 2019-2032.

 

For further information on Market Impact by Therapies, Download Hepatic Encephalopathy Market sample @ Hepatic Encephalopathy Market Landscape 

 

Hepatic Encephalopathy Epidemiology Segmentation

  • As per DelveInsight’s analysis, the total diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM were found to be 337,141 in 2020. 
  • DelveInsight estimates that the majority of cases of Hepatic Encephalopathy are occupied by males as compared to females. There were a total of 149,048 male and 55,970 female cases of Hepatic Encephalopathy in 2020 in the United States.

 

The Hepatic Encephalopathy Report offers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Hepatic Encephalopathy 
  • Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
  • Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
  • Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy

 

Know how Hepatic Encephalopathy Epidemiological Trends are going to look like in 2032 for the 7MM by downloading @ Hepatic Encephalopathy Epidemiological Insights

 

Hepatic Encephalopathy Pipeline Therapies and Key Companies

  • AXA1665: Axcella Health
  • Rifaximin (SSD): Bausch Health/Salix Pharmaceuticals
  • GR3027 (Golexanolone): Umecrine Cognition
  • VE303: Vedanta Biosciences

 

To know about more pipeline therapies under different development phases visit @ Hepatic Encephalopathy Pipeline Assessment

 

Scope of the Hepatic Encephalopathy Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hepatic Encephalopathy Companies: Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Health/Salix Pharmaceuticals
  • Key Hepatic Encephalopathy Pipeline Therapies: Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303
  • Hepatic Encephalopathy Therapeutic Assessment: Hepatic Encephalopathy current marketed and emerging therapies
  • Hepatic Encephalopathy Market Dynamics: Hepatic Encephalopathy market drivers and barriers 
  • Competitive Intelligence Analysis: Porter’s five forces, SWOT analysis, PESTLE analysis, BCG Matrix, Market entry strategies
  • Key Cross Competition, KOL’s views, Hepatic Encephalopathy Unmet Needs, Hepatic Encephalopathy Market Access and Reimbursement

 

Table of Contents 

1

Key Insights

2

Report Introduction to Hepatic Encephalopathy

3

Hepatic Encephalopathy: Market overview at a glance

4

Hepatic Encephalopathy Market: Future Perspective

5

Executive Summary of Hepatic Encephalopathy (HE)

6

Key Events in Hepatic Encephalopathy

7

Disease Background and Overview: Hepatic Encephalopathy

8

Hepatic Encephalopathy Epidemiology and Patient Population (7MM)

9

Hepatic Encephalopathy Patient Journey

10

Hepatic Encephalopathy Marketed Therapies

11

Hepatic Encephalopathy Emerging Drugs

12

Hepatic Encephalopathy: Seven Major Market Analysis

13

KOL Views

14

Hepatic Encephalopathy Market Drivers

15

Hepatic Encephalopathy Market Barriers

16

Hepatic Encephalopathy SWOT Analysis

17

Hepatic Encephalopathy Unmet Needs

18

Reimbursement and Market Access in Hepatic Encephalopathy

19

Appendix

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

Discover more about therapy set to grab substantial Hepatic Encephalopathy market share @ Hepatic Encephalopathy Market Share

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles